Yıl: 2022 Cilt: 32 Sayı: 2 Sayfa Aralığı: 120 - 127 Metin Dili: Türkçe DOI: 10.5336/dermato.2021-86988 İndeks Tarihi: 20-09-2022

Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme

Öz:
Mukolitik ve nefroprotektif bir ajan olan N-asetilsistein, yaygın olarak asetaminofen toksisitesinde antidot olarak kullanılır. Bir sistein donörü olarak hareket ederek, antioksidan, antiinflamatuar ve antiproliferatif etkileri oluşturur. Nörotransmitter düzeylerinde de değişikliğe yol açar. Fibroblastların ve keratinositlerin çoğalmasını engeller, vazodilatasyona neden olur. Bu özellikleriyle nöroloji, psikiyatri, nefroloji, maligniteler, çeşitli vasküler bozukluklar ve akciğer hastalıklarına kadar çok çeşitli tıbbi alanlarda potansiyel kullanım alanı bulmuştur. Dermatoloji alanındaki kullanımları, sistemik ve topikal formda olmak üzere küçük çaplı çalışmalar ve olgu sunumları, vaka serileri şeklinde literatürde bildirilmiştir. Burada sırasıyla ilaç reaksiyonları (toksik epidermal nekroliz ve ilaç hipersensitivite sendromu); trikotillomani, trikoteiromani, onikotillomani gibi deri yolma bozukluklarını içeren psikodermatozlar; iktiyozlar, kontakt dermatit ve atopik dermatit gibi epidermal bariyer/keratinizasyon bozuklukları olan hastalıklar; kseroderma pigmentozum, melazma, psödoporfiri gibi fotodermatozlar; sistemik skleroz ve lupus eritematozus gibi konnektif doku hastalıkları; yara iyileşmesi ve büllöz morfea; polikistik over sendromu, hiperandrojenizm, akne ve alopesideki kullanım alanlarına değinilecektir. Her ne kadar ilacın temini kolay ve güvenlik profili iyi olsa da daha geniş çapta kullanım için kanıt düzeyinin daha yüksek olması gerekli görülmektedir. Bu derlemede, N-asetilsisteinin dermatoloji alanındaki mevcut çeşitli kullanım alanları ve etki mekanizmaları gözden geçirilerek, günlük dermatoloji pratiğinde göz ardı edilen potansiyel kullanım alanlarına dikkat çekilmesi hedeflenmiştir. Dermatolojik hastalıklar için güvenli ve umut veren bir seçenek olabileceği düşünülmektedir.
Anahtar Kelime:

N-Acetylcysteine Uses in Dermatology Traditional Compilation: Traditional Review

Öz:
N-acetylcysteine, a mucolytic and nephroprotective agent, is frequently used as an antidote to acetaminophen toxicity. Acting as a cysteine donor, it has antioxidant, anti-inflammatory and antiproliferative effects. It also causes changes in neurotransmitter levels. It prevents the proliferation of fibroblasts and keratinocytes, generates vasodilation. With these properties, it has found potential use in a wide variety of medical fields, from neurology, psychiatry, nephrology, malignancies, various vascular disorders to lung diseases. Their use in dermatology has been reported in the literature in the form of small-scale studies, case reports, case series, in systemic and topical forms. Here, respectively; the usage areas in drug reactions (toxic epidermal necrolysis and drug hypersensitivity syndrome); psychodermatoses including skin picking disorders such as trichotillomania, trichotillomania, onychotillomania; diseases with epidermal barrier/keratinization disorders such as ichthyoses, contact dermatitis and atopic dermatitis; photodermatoses such as xeroderma pigmentosum, melasma, pseudoporphyria; connective tissue diseases such as systemic sclerosis and lupus erythematosus; wound healing and bullous morphea; polycystic ovary syndrome, hyperandrogenism, acne and alopecia will be mentioned. Although the drug is easy to obtain and has a good safety profile, a higher level of evidence is required for wider use. In this review, the current usage areas and mechanisms of action of N-acetylcysteine in dermatology are reviewed and it is aimed to draw attention to the potential usage areas that are overlooked in daily dermatology practice. It is considered to be a safe and promising option for dermatological diseases.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Millea Pj. N-acetylcysteine: multiple clinical applications. Am fam Physician. 2009;80(3):265-9. [PubMed]
  • 2. samuni Y, goldstein s, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830(8):4117- 29. [Crossref] [PubMed]
  • 3. Bavarsad shahripour R, harrigan MR, Alexandrov AV. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014;4(2):108-22. [Crossref] [PubMed] [PMC]
  • 4. holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20(2):123-34. [Crossref] [PubMed]
  • 5. Kerksick C, Willoughby D. The antioxidant role of glutathione and Nacetyl- cysteine supplements and exercise-induced oxidative stress. j Int soc sports Nutr. 2005;2(2):38-44. [Crossref] [PubMed] [PMC]
  • 6. Atkuri KR, Mantovani jj, herzenberg LA, herzenberg LA. N-Acetylcysteine-- a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7(4):355-9. [Crossref] [PubMed] [PMC]
  • 7. Nascimento MM, suliman ME, silva M, Chinaglia T, Marchioro j, hayashi sY, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int. 2010;30(3):336-42. [Crossref] [PubMed]
  • 8. Moran MM, Mcfarland K, Melendez RI, Kalivas PW, seamans jK. Cystine/ glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. j Neurosci. 2005;25(27):6389-93. [Crossref] [PubMed] [PMC]
  • 9. gere-Pászti E, jakus j. The effect of N-acetylcysteine on amphetaminemediated dopamine release in rat brain striatal slices by ion-pair reversed- phase high performance liquid chromatography. Biomed Chromatogr. 2009;23(6):658-64. [Crossref] [PubMed]
  • 10. sekharam M, Trotti A, Cunnick jM, Wu j. suppression of fibroblast cell cycle progression in g1 phase by N-acetylcysteine. Toxicol Appl Pharmacol. 1998;149(2):210-6. [Crossref] [PubMed]
  • 11. Allegra L, Dal sasso M, Bovio C, Massoni C, fonti E, Braga PC. human neutrophil oxidative bursts and their in vitro modulation by different Nacetylcysteine concentrations. Arzneimittelforschung. 2002;52(9):669- 76. [Crossref] [PubMed]
  • 12. Redondo P, Ruiz de Erenchun f, Iglesias ME, Monedero P, Quintanilla E. Toxic epidermal necrolysis. Treatment with pentoxifylline. Br j Dermatol. 1994;130(5):688-9. [Crossref] [PubMed]
  • 13. Vélez A, Moreno jC. Toxic epidermal necrolysis treated with N-acetylcysteine. j Am Acad Dermatol. 2002;46(3):469-70. [Crossref] [PubMed]
  • 14. saavedra C, Cárdenas P, Castellanos h, Contreras K, Castro jR. Cephazolin- induced toxic epidermal necrolysis treated with intravenous immunoglobulin and N-acetylcysteine. Case Reports Immunol. 2012;2012:931528. [Crossref] [PubMed] [PMC]
  • 15. Yavuz h, Emiroglu M. Toxic epidermal necrolysis treated with N-acetylcysteine. Pediatr Int. 2014;56(5):e52-4. [Crossref] [PubMed]
  • 16. Moling O, Tappeiner L, Piccin A, Pagani E, Rossi P, Rimenti g, et al. Treatment of DIhs/DREss syndrome with combined N-acetylcysteine, prednisone and valganciclovir--a hypothesis. Med sci Monit. 2012;18(7):Cs57-62. [Crossref] [PubMed] [PMC]
  • 17. Walsh sA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DREss): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):6-11. [Crossref] [PubMed]
  • 18. jose j, Klein R. successful treatment of sulfasalazine-induced DREss syndrome with corticosteroids and N-acetylcysteine. Pharmacotherapy. 2011;31:1043. [Crossref]
  • 19. grant jE, Odlaug BL, Kim sW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch gen Psychiatry. 2009;66(7):756-63. [Crossref] [PubMed]
  • 20. Rodrigues-Barata AR, Tosti A, Rodríguez-Pichardo A, Camacho- Martínez f. N-acetylcysteine in the Treatment of Trichotillomania. Int j Trichology. 2012;4(3):176-8. [Crossref] [PubMed] [PMC]
  • 21. Taylor M, Bhagwandas K. N-acetylcysteine in trichotillomania: a panacea for compulsive skin disorders? Br j Dermatol. 2014;171(5):1253-5. [Crossref] [PubMed]
  • 22. Bloch Mh, Panza KE, grant jE, Pittenger C, Leckman jf. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double- blind, placebo-controlled add-on trial. j Am Acad Child Adolesc Psychiatry. 2013;52(3):231-40. [PubMed] [PMC]
  • 23. salas-Callo CI, Pirmez R. Trichoteiromania: good response to treatment with n-acetylcysteine. skin Appendage Disord. 2019;5(4):242-5. [Crossref] [PubMed] [PMC]
  • 24. Miller jL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am j Med genet A. 2014;164A(2):421-4. [Crossref] [PubMed]
  • 25. grant jE, Chamberlain sR, Redden sA, Leppink EW, Odlaug BL, Kim sW. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. jAMA Psychiatry. 2016;73(5):490-6. [Crossref] [PubMed]
  • 26. Taylor M, Bhagwandas K. Trichotillosis, skin picking and N-acetylcysteine. j Am Acad Dermatol. 2015;72 suppl 1:AB117. [Crossref]
  • 27. ghanizadeh A, Derakhshan N, Berk M. N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial. Antiinflamm Antiallergy Agents Med Chem. 2013;12(3):223-8. [Crossref] [PubMed]
  • 28. Berk M, jeavons s, Dean OM, Dodd s, Moss K, gama Cs, et al. Nailbiting stuff? The effect of N-acetyl cysteine on nail-biting. CNs spectr. 2009;14(7):357-60. [Crossref] [PubMed]
  • 29. Redondo P, Bauzá A. Topical N-acetylcysteine for lamellar ichthyosis. Lancet. 1999;354(9193):1880. [Crossref] [PubMed]
  • 30. sarici su, sahin M, Yurdakök M. Topical N-acetylcysteine treatment in neonatal ichthyosis. Turk j Pediatr. 2003;45(3):245-7. [PubMed]
  • 31. Bassotti A, Moreno s, Criado E. successful treatment with topical Nacetylcysteine in urea in five children with congenital lamellar ichthyosis. Pediatr Dermatol. 2011;28(4):451-5. [Crossref] [PubMed]
  • 32. Deffenbacher B. successful experimental treatment of congenital ichthyosis in an infant. BMj Case Rep. 2013;2013:bcr2013008688. [Crossref] [PubMed] [PMC]
  • 33. Nakai K, Yoneda K, hosokawa Y, Moriue T, Presland RB, fallon Pg, et al. Reduced expression of epidermal growth factor receptor, E-cadherin, and occludin in the skin of flaky tail mice is due to filaggrin and loricrin deficiencies. Am j Pathol. 2012;181(3):969-77. [Crossref] [PubMed]
  • 34. Nakai K, Yoneda K, Murakami Y, Koura A, Maeda R, Tamai A, et al. Effects of topical N-acetylcysteine on skin hydration/transepidermal water loss in healthy volunteers and atopic dermatitis patients. Ann Dermatol. 2015;27(4):450-1. [Crossref] [PubMed] [PMC]
  • 35. senaldi g, Pointaire P, Piguet Pf, grau gE. Protective effect of N-acetylcysteine in hapten-induced irritant and contact hypersensitivity reactions. j Invest Dermatol. 1994;102(6):934-7. [Crossref] [PubMed]
  • 36. Pasche-Koo f, Arechalde A, Arrighi jf, hauser C. Effect of N-acetylcysteine, an inhibitor of tumor necrosis factor, on irritant contact dermatitis in the human. Curr Probl Dermatol. 1995;23:198-206. [Crossref] [PubMed]
  • 37. Kang s, Chung jh, Lee jh, fisher gj, Wan Ys, Duell EA, et al. Topical N-acetyl cysteine and genistein prevent ultraviolet-light-induced signaling that leads to photoaging in human skin in vivo. j Invest Dermatol. 2003;120(5):835-41. [Crossref] [PubMed]
  • 38. Cotter MA, Thomas j, Cassidy P, Robinette K, jenkins N, florell sR, et al. N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res. 2007;13(19):5952-8. [Crossref] [PubMed] [PMC]
  • 39. goodson Ag, Cotter MA, Cassidy P, Wade M, florell sR, Liu T, et al. use of oral N-acetylcysteine for protection of melanocytic nevi against uV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res. 2009;15(23):7434-40. [Crossref] [PubMed] [PMC]
  • 40. Redondo P, Bandrés E, solano T, Okroujnov I, garcía-foncillas j. Vascular endothelial growth factor (VEgf) and melanoma. N-acetylcysteine downregulates VEgf production in vitro. Cytokine. 2000;12(4):374-8. [Crossref] [PubMed]
  • 41. Margaryan NV, gilgur A, seftor EA, Purnell C, Arva NC, gosain AK, et al. Melanocytes affect nodal expression and signaling in melanoma cells: a lesson from pediatric large congenital melanocytic nevi. Int j Mol sci. 2016;17(3):418. [Crossref] [PubMed] [PMC]
  • 42. Kunisada M, hosaka C, Takemori C, Nakano E, Nishigori C. CXCL1 inhibition regulates uVB-induced skin inflammation and tumorigenesis in Xpa-deficient mice. j Invest Dermatol. 2017;137(9):1975-83. [Crossref] [PubMed]
  • 43. Reliene R, fischer E, schiestl Rh. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res. 2004;64(15):5148-53. [Crossref] [PubMed]
  • 44. Demirel C, Kilciksiz s, Evirgen-Ayhan s, gurgul s, Erdal N. The preventive effect of N-acetylcysteine on radiation-induced dermatitis in a rat model. j BuON. 2010;15(3):577-82. [PubMed]
  • 45. Kim jA, Baker Dg, hahn ss, goodchild NT, Constable WC. Topical use of N-acetylcysteine for reduction of skin reaction to radiation therapy. semin Oncol. 1983;10(1 suppl 1):86-92. [PubMed]
  • 46. sehgal VN, Verma P, srivastava g, Aggarwal AK, Verma s. Melasma: treatment strategy. j Cosmet Laser Ther. 2011;13(6):265-79. [Crossref] [PubMed]
  • 47. Njoo MD, Menke hE, Pavel W, Westerhof W. N-acetylcysteine as a bleaching agent in the treatment of melasma. j Eur Acad Dermatol Venereol. 1997;9:86-7. [Crossref]
  • 48. Vadoud-seyedi j, de Dobbeleer g, simonart T. Treatment of haemodialysis- associated pseudoporphyria with N-acetylcysteine: report of two cases. Br j Dermatol. 2000;142(3):580-1. [Crossref] [PubMed]
  • 49. Cooke Ns, McKenna K. A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine. Clin Exp Dermatol. 2007;32(1):64-6. [PubMed]
  • 50. Velioglu A, Ergun T, Ozener C. Pseudoporphyria in a peritoneal dialysis patient. Perit Dial Int. 2015;35(2):234-5. [Crossref] [PubMed] [PMC]
  • 51. Katoulis AC, ferra D, Toumbis E, Papadavid E, Kanelleas A, Panayiotides I, et al. Pseudoporphyria associated with nonhemodialyzed renal insufficiency, successfully treated with oral N-acetylcysteine. Case Rep Dermatol Med. 2013;2013:271873. [Crossref] [PubMed] [PMC]
  • 52. furst DE, Clements Pj, harris R, Ross M, Levy j, Paulus hE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979;38(4):356-61. [Crossref] [PubMed] [PMC]
  • 53. sambo P, Amico D, giacomelli R, Matucci-Cerinic M, salsano f, Valentini g, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: A pilot study. j Rheumatol 2001;28:2257-62.
  • 54. Rosato E, Borghese f, Pisarri s, salsano f. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol. 2009;28(12):1379-84. [Crossref] [PubMed]
  • 55. Lai zW, hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, et al. N acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double blind, placebo controlled trial. Arthritis Rheum 2012;64:2937 46. [Crossref] [PubMed] [PMC]
  • 56. Tewthanom K, janwitayanujit s, Totemchockcyakarn K, Panomvana Na Ayudhya D. The effect of high dose of N acetylcysteine in lupus nephritis: A case report and literature review. j Clin Pharm Ther 2010;35:483 5. [Crossref] [PubMed]
  • 57. garcia Rj, francis L, Dawood M, Lai zW, faraone sV, Perl A. Attention deficit and hyperactivity disorder scores are elevated and respond to N acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:1313 8. [Crossref] [PubMed] [PMC]
  • 58. Ozkaya h, Bahat g, Tufan A, Dogan h, Bilicen z, Karan MA. successful treatment of non-healing pressure ulcers with topical n-acetyl cysteine. j Wound Care. 2015;24(12):606, 608-11. [Crossref] [PubMed]
  • 59. Deniz M, Borman h, seyhan T, haberal M. An effective antioxidant drug on prevention of the necrosis of zone of stasis: N-acetylcysteine. Burns. 2013;39(2):320-5. [Crossref] [PubMed]
  • 60. Demir EO, Cakmak gK, Bakkal h, Turkcu uO, Kandemir N, Demir As, et al. N-acetyl-cysteine improves anastomotic wound healing after radiotherapy in rats. j Invest surg. 2011;24(4):151-8. [Crossref] [PubMed]
  • 61. Aktunc E, Ozacmak Vh, Ozacmak hs, Barut f, Buyukates M, Kandemir O, et al. N-acetyl cysteine promotes angiogenesis and clearance of free oxygen radicals, thus improving wound healing in an alloxan-induced diabetic mouse model of incisional wound. Clin Exp Dermatol. 2010;35(8):902-9. [Crossref] [PubMed]
  • 62. Rosato E, Veneziano ML, Di Mario A, Molinaro I, Pisarri s, salsano f. ulcers caused by bullous morphea: successful therapy with N-acetylcysteine and topical wound care. Int j Immunopathol Pharmacol. 2013;26(1):259-62. [Crossref] [PubMed]
  • 63. Oner g, Muderris II. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur j Obstet gynecol Reprod Biol. 2011;159(1):127-31. [PubMed]
  • 64. Thakker D, Raval A, Patel I, Walia R. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet gynecol Int. 2015;2015:817849. [Crossref] [PubMed] [PMC]
  • 65. sahib As, Al-Anbari hh, salih M, Abdullah f. Effect of oral antioxidants on lesion counts associated with oxidative stress and inflammation in patients with papulopustular acne. j Clin Exp Dermatol Res. 2012;3(5):163. [Crossref]
  • 66. Montes Lf, Wilborn Wh, Montes CM. Topical acne treatment with acetylcysteine: clinical and experimental effects. skinmed. 2012;10(6):348-51. [PubMed]
  • 67. Eroshenko D, Polyudova T, Korobov V. N-acetylcysteine inhibits growth, adhesion and biofilm formation of gram-positive skin pathogens. Microb Pathog. 2017;105:145-52. [Crossref] [PubMed]
  • 68. upton jh, hannen Rf, Bahta AW, farjo N, farjo B, Philpott MP. Oxidative stress-associated senescence in dermal papilla cells of men with androgenetic alopecia. j Invest Dermatol. 2015;135(5):1244-52. [Crossref] [PubMed]
  • 69. D'Agostini f, Bagnasco M, giunciuglio D, Albini A, De flora s. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int j Oncol. 1998;13(2):217-24. [Crossref] [PubMed]
  • 70. Li j, Xu L, Deng X, jiang C, Pan C, Chen L, et al. N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain. 2016;157(8):1711-23. [Crossref] [PubMed]
  • 71. Kamboj ss, Vasishta RK, sandhir R. N-acetylcysteine inhibits hyperglycemia-induced oxidative stress and apoptosis markers in diabetic neuropathy. j Neurochem. 2010;112(1):77-91. [Crossref] [PubMed]
APA KALKAN G (2022). Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. , 120 - 127. 10.5336/dermato.2021-86988
Chicago KALKAN GÖKNUR Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. (2022): 120 - 127. 10.5336/dermato.2021-86988
MLA KALKAN GÖKNUR Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. , 2022, ss.120 - 127. 10.5336/dermato.2021-86988
AMA KALKAN G Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. . 2022; 120 - 127. 10.5336/dermato.2021-86988
Vancouver KALKAN G Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. . 2022; 120 - 127. 10.5336/dermato.2021-86988
IEEE KALKAN G "Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme." , ss.120 - 127, 2022. 10.5336/dermato.2021-86988
ISNAD KALKAN, GÖKNUR. "Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme". (2022), 120-127. https://doi.org/10.5336/dermato.2021-86988
APA KALKAN G (2022). Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. Türkiye Klinikleri Dermatoloji Dergisi, 32(2), 120 - 127. 10.5336/dermato.2021-86988
Chicago KALKAN GÖKNUR Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. Türkiye Klinikleri Dermatoloji Dergisi 32, no.2 (2022): 120 - 127. 10.5336/dermato.2021-86988
MLA KALKAN GÖKNUR Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. Türkiye Klinikleri Dermatoloji Dergisi, vol.32, no.2, 2022, ss.120 - 127. 10.5336/dermato.2021-86988
AMA KALKAN G Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. Türkiye Klinikleri Dermatoloji Dergisi. 2022; 32(2): 120 - 127. 10.5336/dermato.2021-86988
Vancouver KALKAN G Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme. Türkiye Klinikleri Dermatoloji Dergisi. 2022; 32(2): 120 - 127. 10.5336/dermato.2021-86988
IEEE KALKAN G "Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme." Türkiye Klinikleri Dermatoloji Dergisi, 32, ss.120 - 127, 2022. 10.5336/dermato.2021-86988
ISNAD KALKAN, GÖKNUR. "Dermatolojide N-Asetilsistein Kullanım Alanları: Geleneksel Derleme". Türkiye Klinikleri Dermatoloji Dergisi 32/2 (2022), 120-127. https://doi.org/10.5336/dermato.2021-86988